Conditioning regimens used in 320 RIC and 196 MAC allogeneic transplantations for myeloma
| Regimen . | T-cell depletion . | Total . | ||
|---|---|---|---|---|
| No . | Yes . | Unknown . | ||
| RIC | ||||
| Fludarabine + TBI | 57 (17.8) | 4 (1.2) | 6 (1.9) | 67 (20.9) |
| Fludarabine + melphalan | 41 (12.8) | 84 (26.3) | 1 (0.3) | 127 (39.4) |
| Fludarabine + busulfan | 5 (1.6) | 75 (23.4) | 2 (0.6) | 82 (25.5) |
| Other | 15 (4.7) | 29 (9.1) | 1 (0.3) | 45 (14.1) |
| MAC | ||||
| Melphalan + TBI | 44 (22.4) | 14 (7.1) | 14 (7.1) | 72 (36.7) |
| Cyclophosphamide + TBI | 25 (12.8) | 66 (33.7) | 3 (1.5) | 94 (48.0) |
| Busulfan + cyclophosphamide | 5 (2.6) | 10 (5.1) | 2 (1.0) | 17 (8.7) |
| Other | 8 (3.6) | 5 (2.6) | 0 (0.0) | 13 (6.6) |
| Regimen . | T-cell depletion . | Total . | ||
|---|---|---|---|---|
| No . | Yes . | Unknown . | ||
| RIC | ||||
| Fludarabine + TBI | 57 (17.8) | 4 (1.2) | 6 (1.9) | 67 (20.9) |
| Fludarabine + melphalan | 41 (12.8) | 84 (26.3) | 1 (0.3) | 127 (39.4) |
| Fludarabine + busulfan | 5 (1.6) | 75 (23.4) | 2 (0.6) | 82 (25.5) |
| Other | 15 (4.7) | 29 (9.1) | 1 (0.3) | 45 (14.1) |
| MAC | ||||
| Melphalan + TBI | 44 (22.4) | 14 (7.1) | 14 (7.1) | 72 (36.7) |
| Cyclophosphamide + TBI | 25 (12.8) | 66 (33.7) | 3 (1.5) | 94 (48.0) |
| Busulfan + cyclophosphamide | 5 (2.6) | 10 (5.1) | 2 (1.0) | 17 (8.7) |
| Other | 8 (3.6) | 5 (2.6) | 0 (0.0) | 13 (6.6) |
Values indicate no. of patients (%) unless otherwise indicated.